Novocure (NVCR) Misses Q3 EPS by 6c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. RTX
9. S
10. COF

Go back to Novocure (NVCR) Misses Q3 EPS by 6c

Novocure Reports Third Quarter 2021 Financial Results and Provides Company Update

October 28, 2021 6:30 AM EDT

Quarterly net revenues of $133.6 million with 77% gross margin

Last patient enrolled in phase 3 pivotal INNOVATE-3 trial for recurrent ovarian cancer

ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2021, highlighting commercial strength and strategic investment across clinical, product development and commercial initiatives intended to fuel future growth. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). TTFields are electric fields that disrupt cancer... More